Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: CCA, ACC

Medivir AB - Interim Report January - June 2020


HUDDINGE, Sweden, Aug. 20, 2020 /PRNewswire/ --

April - June
Significant events during the quarter           

Financial summary for the quarter           

January - June
Financial summary            

Significant events after the end of the quarter           

Conference call for investors, analysts and the media
The Interim Report January - June 2020 will be presented by Medivir's President & CEO, Uli Hacksell.

Time: Thursday, August 20, 2020, at 14.00 (CET).

Phone numbers for participants from:
Sweden + 46 8 505 583 53
Europe + 44 33 3300 9034
US + 1 833 526 83 95

The conference call will also be streamed via a link on the website: www.medivir.com
The presentation will be available on Medivir's website after completion of the conference.
 

CEO's message

During the quarter, our proprietary and wholly owned candidate drug, MIV-818, was granted orphan drug designation in both the EU and the US for the treatment of hepatocellular carcinoma. These are important milestones that can facilitate the path to potential market approvals for MIV-818. Medivir has also recruited a new CEO in the form of Yillmaz Mahshid, who from this autumn will lead the development of the company and our exciting projects.

MIV-818 has potential to be the first liver cancer-targeted, orally administered drug that can help patients with advanced liver cancer. During the quarter MIV-818 was granted orphan drug designation in both the EU and the US for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The classification provides a number of benefits that can lead to a smoother, faster and less costly path to potential market approval. It also provides the opportunity for market exclusivity, seven years in the US and ten years in the EU after approval.

In Asia, unlike in the western world, HCC is a common disease and therefore drugs against HCC are not given orphan drug status in Asia. As a consequence, the clinical development program for MIV-818 will be different in Asia compared to the United States and the European Union. I envision that going forward we need to work with a partner who can be responsible for the development and sale of MIV-818 in the Asian market in order to maximize the value of MIV-818 also in this region.

In March, positive data from our phase Ia study were presented and shortly thereafter, the first patient with advanced liver cancer was dosed in the current phase Ib study with MIV-818. The study will determine the safety and tolerability profile of MIV-818 but will also further investigate the efficacy of MIV-818. The ongoing Covid-19 pandemic has affected patient recruitment, which has been taken into account. However, we see today no obstacles to present the overall results from the study during the first quarter of 2021.

With our human and financial resources invested in MIV-818, we have not yet been able to begin the preclinical development of MIV-828, the candidate substance that focuses on the treatment of blood cancer. 

Regarding our other clinical projects, i.e. remetinostat, birinapant and MIV-711, our focus is on business development. However, I would like to mention that we have two ongoing investigator-initiated studies of remetinostat, in patients with basal cell carcinoma (BCC) and squamous cell carcinoma, respectively, and that preliminary results from the BCC study were very encouraging. In another investigator-initiated study, a combination of birinapant and radiotherapy is being evaluated in patients with recurrence of squamous cell carcinoma in the head and neck region.

At the end of May, we were able to present that Yilmaz Mahshid, with long and broad experience from qualified roles in the life science sector, has been recruited to take over as CEO of Medivir. Yilmaz Mahshid will take over in September and I am convinced that he will be perfect as the new CEO of Medivir. Yilmaz is extremely qualified and has the background, drive and strategic thinking that our exciting company needs. I will remain as CEO until Yilmaz assumes his position. Some time after the handover, I will return to work only as a Board Member.

This is thus my last quarterly report as CEO and I would like to take this opportunity to thank you for the trust, from employees and colleagues as well as from shareholders and the Board, during the almost two years I have had the privilege of leading the company. It has been a journey where we have reshaped Medivir, sharpened the company's focus and implemented radical organizational changes.  At the same time, we have seen success, especially in the development of MIV-818, which shows that our proprietary and wholly owned projects have great potential. Medivir of today is a flexible and efficient development company that uses its resources where they can create the greatest value. It will be very exciting to follow the development going forward.

Uli Hacksell
President & CEO

For further information, please contact

Uli Hacksell, CEO, +46 (0) 8 5468 3100
Magnus Christensen, CFO, +46 (0)73 125 0620

This report has not been subject to auditors' review.

The information was submitted for publication at 08.30 CET on 20 August 2020.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/medivir-ab---interim-report-january---june-2020,c3176549

The following files are available for download:

https://mb.cision.com/Main/652/3176549/1294604.pdf

INTERIM REPORT JANUARY â?" JUNE 2020 (PDF)

 

SOURCE Medivir


These press releases may also interest you

at 20:00
A September 28 article on the South China Morning Post reports on the increase in demand for cosmetic surgery in Southeast Asia following the loosening of restrictions for non-essential businesses during the pandemic. The article speculates that the...

at 19:46
This week, AMCP Nexus 2020 Virtual welcomes more than 1,800 managed care pharmacy professionals for five days of essential learning opportunities centered on "making the way for innovation."...

at 18:00
LifeLearn Animal Health announced that veterinarian and corporate veterinary industry consultant Dr. Anne Dagner has joined LifeLearn Industry Solutions as Account Manager. "We're very pleased and excited to have Anne as part of the LifeLearn team,"...

at 18:00
More than 50, 000 people from across the country are expected to take part in Light The Night, Take Back The Light ? an annual flagship event hosted by The Leukemia & Lymphoma Society of Canada (LLSC). For the first time in the organization's...

at 17:47
John K. Maesaka, M.D., is being recognized by Continental Who's Who as a Top Nephrologist for his dedication to research in the field of Medicine and for his professional excellence with Langone Health.            As a seasoned and distinguished...

at 17:47
Katharine A. Murphy-Brown, DMD, is being recognized by Continental Who's Who as a Top Dentist for her outstanding achievements in the field of Medicine and acknowledgment of her dedication and commitment as Owner of her Private Practice. ...



News published on 20 august 2020 at 02:50 and distributed by: